Drug Search Results
More Filters [+]

LNP-1265

Alternative Names: LNP-1265, LNP 1265, LNP1265
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

In vivo CRISPR/Cas9-based Factor 9 gene insertion therapy. (Sourced from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-scientific-advancements-across-diversified)

Mechanisms of Action: Gene Therapy

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LNP-1265

Countries in Clinic: Germany

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Hemophilia A|Hemophilia B

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BEYOND-9

P2

Not yet recruiting

Hemophilia B|Hemophilia A

2032-07-03

24%

BEYOND-9

P2

Not yet recruiting

Hemophilia B|Hemophilia A

2032-07-03

24%

R131L1265-HEMB-2318

P2

Not yet recruiting

Hemophilia B

2029-07-27

Recent News Events

Date

Type

Title